High-expression EGFR/cell membrane chromatography-online-high-performance liquid chromatography/mass spectrometry: Rapid screening of EGFR antagonists from Semen Strychni

Rapid Communications in Mass Spectrometry

Volumn 26, Issue 17, 2012, Pages 2027-2032

  Sun, Meng ^a   Guo, Ying ^a   Dai, Bingling ^a   Wang, Chen ^a   He, Langchong ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CELL PROLIFERATION; CELL SIGNALING; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEDICINE; MEMBRANES;

ACTIVE COMPOUNDS; ANALYTICAL METHOD; CELL MEMBRANE CHROMATOGRAPHIES; CELL MEMBRANE STATIONARY PHASE; CHROMATOGRAPHY MODELING; EXPRESSION LEVELS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETRIES; RAPID SCREENING; SEPARATION AND IDENTIFICATION; TRADITIONAL CHINESE MEDICINE;

MASS SPECTROMETRY;

EID: 84864757738     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6318     Document Type: Article

References (45)

1. F. Ciardiello, G. Tortora,. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160.
2. P. Blume-Jensen, T. Hunter,. Oncogenic kinase signalling. Nature 2001, 411, 355.
3. J. Mendelsohn,. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002, 20, 1.
4. F. Ciardiello, G. Tortora,. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur. J. Cancer 2003, 39, 1348.
5. M. Scaltriti, J. Baselga,. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res. 2006, 12, 5268.
6. J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin, R. B. Cohen, C. U. Jones, R. Sur, D. Raben, J. Jassem,. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567.
7. R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky,. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626.
8. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, A. R. Bianco, G. Tortora,. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000, 6, 2053.
9. U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, F. De Rosa, J. Milanowski, H. Karnicka-Mlodkowski, M. Pesek, P. Serwatowski,. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007, 25, 1545.
10. C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman,. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355, 2733.
11. G. E. Konecny, M. D. Pegram, N. Venkatesan, R. Finn, G. Yang, M. Rahmeh, M. Untch, D. W. Rusnak, G. Spehar, R. J. Mullin,. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66, 1630.
12. C. A. Hudis,. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357, 39.
13. M. S. Gordon, D. Matei, C. Aghajanian, U. A. Matulonis, M. Brewer, G. F. Fleming, J. D. Hainsworth, A. A. Garcia, M. D. Pegram, R. J. Schilder,. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 2006, 24, 4324.
14. C. Yang, J. Shih, T. Chao, C. Tsai, C. Yu, P. Yang, M. Streit, M. Shahidi, V. Miller,. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial, in Proc. ASCO Annual Meeting, 2008. J. Clin. Oncol. 2008, 26, Abstract No. 8026.
15. D. Bebb, A. Brade, C. Smith, S. Rorke, I. Sherman,. Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. J. Clin. Oncol. 2008, 26, S3037.
16. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. Von Pawel, S. Thongprasert, E. H. Tan, K. Pemberton, V. Archer,. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet 2005, 366, 1527.
17. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon,. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497.
18. K. Leslie, M. Sill, K. Darcy, A. Baron, J. Wilken, A. Godwin, L. Cook, R. Schilder, J. Schilder, N. Maihle,. Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. J. Clin. Oncol. 2009, 27, e16542.
19. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore,. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719.
20. R. Nahta, M. C. Hung, F. J. Esteva,. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64, 2343.
21. E. H. Romond, E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer Jr, N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman,. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673.
22. A. Lievre, J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, J. F. Côté, G. Tomasic, C. Penna, M. Ducreux,. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992.
23. M. Li, X. F. Hou, J. Zhang, S. C. Wang, Q. Fu, L. C. He,. Applications of HPLC/MS in the analysis of traditional Chinese medicines. J. Pharm. Anal. 2011, 1, 81.
24. Y. Zhan, M. Sun, Y. Chen, Y. M. Zhang,. Determination of taspine using HPLC-MS, and its effect on EGFR in A431 and HEK293/EGFR cells. Chromatographia 2011, 74, 383.
25. H. Li, J. Tang, R. Liu, M. Lin, B. Wang, Y. Lv, H. Huang, C. Zhang, W. Zhang,. Characterization and identification of steroidal alkaloids in the Chinese herb Veratrum nigrum L. by high-performance liquid chromatography/ electrospray ionization with multi-stage mass spectrometry. Rapid. Commun. Mass Spectrom. 2007, 21, 869.
26. Y. Liu, Y. Xiao, X. Xue, X. Zhang, X. Liang,. Systematic screening and characterization of novel bufadienolides from toad skin using ultra-performance liquid chromatography/electrospray ionization quadrupole time-of-flight mass spectrometry. Rapid. Commun. Mass Spectrom. 2010, 24, 667.
27. L. He, G. Yang, X. Geng,. Enzymatic activity and chromatographic characteristics of the cell membrane immobilized on silica surface. Chin. Sci. Bull. 1999.
28. L. He, S. Wang, X. Geng,. Coating and fusing cell membranes onto a silica surface and their chromatographic characteristics. Chromatographia 2001, 54, 71.
29. X. Pan, C. Wang, F. Wang, P. Li, Z. Hu, Y. Shan, J. Zhang,. Development of 5-fluorouracil derivatives as anticancer agents. Curr. Med. Chem. 2011, 18, 4538.
30. M. Sun, Y. Zhang, J. Zhang, S. Wang, L. He,. A high expression EGFR/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening EGFR antagonists from Rhizoma Polygoni Cuspidati. Acta Pharmaceutica Sinica B 2011, 1, 115.
31. M. Sun, J. Ren, H. Du, Y. Zhang, J. Zhang, S. Wang, L. He,. A combined A431 cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening compounds from total alkaloid of Radix Caulophylli acting on the human EGFR. J. Chromatogr. B 2010, 878, 2712.
32. S. Wang, M. Sun, Y. Zhang, H. Du, L. He,. A new A431/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening epidermal growth factor receptor antagonists from Radix sophorae flavescentis. J. Chromatogr. A 2010, 1217, 5246.
33. C. Wang, S. Wang, Q. Chen, L. He,. A capillary gas chromatography- selected ion monitoring mass spectrometry method for the analysis of atractylenolide I in rat plasma and tissues, and application in a pharmacokinetic study. J. Chromatogr. B 2008, 863, 215.
34. L. Wang, J. Ren, M. Sun, S. Wang,. A combined cell membrane chromatography and online HPLC/MS method for screening compounds from Radix Caulophylli acting on the human [alpha] 1A-adrenoceptor. J. Pharm. Biomed. Anal. 2010, 51, 1032.
35. J. Ren, D. Dai, H. Du, M. Sun, S. Wang,. Prostate cell membrane chromatography-LC/MS method for screening α 1A-adrenoceptor antagonists from Lotus plumule. Chromatographia 2011, 1.
36. T. Efferth, P. C. H. Li, V. S. B. Konkimalla, B. Kaina,. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13, 353.
37. K. H. Lee,. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutr. 2000, 3, 515.
38. S. M. Lee, J. I. Kwon, Y. H. Choi, H. S. Eom, G. Y. Chi,. Induction of G2/M arrest and apoptosis by water extract of Strychni Semen in human gastric carcinoma AGS cells. Phytother. Res. 2008, 22, 752.
39. X. K. Deng, W. Yin, W. D. Li, F. Z. Yin, X. Y. Lu, X. C. Zhang, Z. C. Hua, B. C. Cai,. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism. J. Ethnopharmacol. 2006, 106, 179.
40. X. Deng, F. Yin, X. Lu, B. Cai, W. Yin,. The apoptotic effect of brucine from the seed of Strychnos nux-vomica on human hepatoma cells is mediated via Bcl-2 and Ca2+ involved mitochondrial pathway. Toxicol. Sci. 2006, 91, 59.
41. W. P. Deng, M. W. Chao, W. F. Lai, C. Sun, C. Y. Chung, C. C. Wu, I. Lin, J. J. Hwang, C. H. Wu, W. T. Chiu,. Correction of malignant behavior of tumor cells by traditional Chinese herb medicine through a restoration of p53. Cancer Lett. 2006, 233, 315.
42. L. He, W. Luo, X. Li, X. Xu, S. Wang, X. Ge,. A wild-type EGFR expression of recombinant HEK293 cells. Chinese Patent 200910022565.9.
43. I. Naruse, T. Ohmori, Y. Ao, H. Fukumoto, T. Kuroki, M. Mori, N. Saijo, K. Nishio,. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa®(ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int. J. Cancer 2002, 98, 310.
44. Y. M. Zhang, L. Zheng, J. Zhang, B. L. Dai, N. Wang, Y. N. Chen, L. C. He,. Anti-tumor activity of taspine by modulating EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo. Planta Med. 2011, 77, 1774.
45. S. C. Wang, M. Sun, Y. M. Zhang, J. Zhang, L. C. He,. EGFR/cell membrane chromatography-online-high performance liquid chromatography/mass spectrometry method for screening EGFR antagonists from Radix Angelicae Pubescentis. Sci. China Chem. 2010, 53, 2357.